Drugs / Calcium leovorin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05355155 Background | May 2022 → May 2023 | hepatocellular carcinoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Calcium leovorin | “Calcium leovorin: 200 mg/m2 ,IV, D1、D2，Q2W” NCT05355155 ↗ |
| Route | Intravenous | “Calcium leovorin: 200 mg/m2 ,IV, D1、D2，Q2W” NCT05355155 ↗ |